Mitigating Paxlovid™-induced drug-drug interaction toxicity: an in silico insight

被引：0
|
作者：
Ta, Giang H. [1 ]
Leong, Max K. [1 ]
机构：
[1] Natl Dong Hwa Univ, Dept Chem, Hualien, Taiwan
来源：
FRONTIERS IN PHARMACOLOGY | 2024年 / 15卷
关键词：
<italic>in silico</italic>; skin permeability; Paxlovid; nirmatrelvir; COVID-19; PENETRATION; PERMEATION; SKIN;
D O I：
10.3389/fphar.2024.1496630
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The clinical drug-drug interaction side-effects of Ritonavir, an ingredient in Paxlovid (TM), have been documented, highlighting the need to explore alternative administration methods for Nirmatrelvir, another drug in the Paxlovid (TM) combination. In this study, the skin permeability potential of Nirmatrelvir was assessed using various in silico models. The prediction results suggest that Nirmatrelvir could be administrated via the transdermal route, offering a promising avenue to enhance the efficacy of anti-COVID-19 agents.
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Warfarin toxicity caused by drug-drug interactions
    van Antwerpen, Monet
    SA PHARMACEUTICAL JOURNAL, 2022, 89 (04) : 40 - 42
  • [42] The Current Status of Time Dependent CYP Inhibition Assay and In Silico Drug-drug Interaction Predictions
    Yan, Zhengyin
    Caldwell, Gary W.
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2012, 12 (11) : 1291 - 1297
  • [43] Screening of drug candidates for their drug-drug interaction potential
    Rodrigues, AD
    Lin, JH
    CURRENT OPINION IN CHEMICAL BIOLOGY, 2001, 5 (04) : 396 - 401
  • [44] Tacrolimus Drug–Drug Interaction with Nirmatrelvir/Ritonavir (Paxlovid™) Managed with Phenytoin
    Morganne Sindelar
    Daniel McCabe
    Elisabeth Carroll
    Journal of Medical Toxicology, 2023, 19 : 45 - 48
  • [45] Paxlovid-Tacrolimus Drug-Drug Interaction in a 23-Year-Old Female Kidney Transplant Patient with COVID-19
    Berar Yanay, Noa
    Bogner, Ido
    Saker, Khader
    Tannous, Elias
    CLINICAL DRUG INVESTIGATION, 2022, 42 (08) : 693 - 695
  • [46] Paxlovid (Nirmatelvir/Ritonavir) and Tacrolimus Drug-Drug Interaction in a Kidney Transplant Patient with SARS-2-CoV infection: A Case Report
    Prikis, Marios
    Cameron, Alexandra
    TRANSPLANTATION PROCEEDINGS, 2022, 54 (06) : 1557 - 1560
  • [47] In silico assessment of cardiovascular adverse effects of drug-drug interactions
    Ivanov, S.
    Semin, M.
    Lagunin, A.
    Filimonov, D.
    Poroikov, V.
    FEBS OPEN BIO, 2018, 8 : 447 - 447
  • [48] In silico assessment of cardiovascular adverse effects of drug-drug interactions
    Ivanov, Sergey
    Lagunin, Alexey
    Filimonov, Dmitry
    Poroikov, Vladimir
    Druzhilovskiy, Dmitry
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2019, 257
  • [49] USING REAL WORLD EVIDENCE (RWE) TO ASSESS DRUG-DRUG INTERACTION (DDI) BETWEEN PAXLOVID AND THE TOP 100 PRESCRIBED DRUGS IN THE US
    Gerhart, J.
    Draica, F.
    Benigno, M.
    Sidhu, G.
    Atkinson, J.
    Reimbaeva, M.
    Francis, D.
    Baillon-Plot, N.
    Damle, B.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 : S17 - S17
  • [50] RHABDOMYOLYSIS INDUCED BY THE CIPROFIBRATE-MICONAZOLE COMBINATION - A NEW DRUG-DRUG INTERACTION
    CLEAU, D
    HUMBLOT, S
    JOBARD, JM
    DELACOUR, JL
    FLORIOT, C
    WAGSCHAL, G
    DAOUDAL, P
    ORY, JP
    SEMAINE DES HOPITAUX, 1995, 71 (31-32): : 966 - 968
12345